Our ICON team in Lima recently came together for a Family Day with purpose - planting trees in the Ate district to support a greener, healthier local community. Events like these reflect what we value most at ICON: team...

Join us at ACoP 2025 for two in-person workshops on October 17th, designed to help you build confidence and gain practical tools for delivering impactful NONMEM presentations. Workshop 1 : New and advanced features of N...

The therapeutic landscape for obesity is changing rapidly. Endpoints focused only on weight loss are no longer enough, and regulators expect measures that capture the entire patient experience. Watch our recent webinar t...

We are proud to share that ICON has been recognised among the Forbes World’s Top Companies for Women 2025. This recognition reflects our continued commitment to creating an inclusive workplace where women can thrive, lea...

Are you navigating complex IRT challenges or planning your next clinical trial? ICON’s experts will be onsite and ready to meet with pharma and biotech leaders looking to optimise their IRT strategy. Whether you're explo...

USP compounding may be fast — but is it costing you quality, compliance, and insight? Join our webinar to learn why GMP is the smarter choice for early phase trials. During this session we will discuss: • The differences...

We’re looking forward to joining the conversation at #OCTNewEngland. On October 15 at 11:30 AM, our General Partner and VP of Operations, Stacey Flattery, will speak on: “Maneuvering with agility in a challenging landsc...

From molecule to market - see how ICON supports oncology sponsors with tailored strategies, from logistics to regulatory, across every phase. Explore oncology case studies: https://ow.ly/Jjhf50WY1mh

ICON is pleased to invite you to an upcoming webinar titled “Introducing ICON strategic solutions FSP services: How this model supports sponsors in Korea,” taking place on 28 October at 2:00 PM KST. This session will pro...

ICON’s Mia Carter joins a panel on Investigational Drug Accountability Management to discuss the real-world friction between clinical sites and sponsors and how to overcome it. Topics include regulatory alignment, effici...

Why do stability studies matter in early drug development? From shelf-life determination to regulatory readiness, a well-designed stability program ensures your drug product remains safe, effective, and reliable. Learn...

ICON will participate in the upcoming Medical Technology Enterprise Consortium (MTEC) webinar on 15 October from 1:00 pm to 2:00 pm. Timothy Bradshaw, Ph.D. and Edward Wright will speak on the topic: "Advancing ICON ea...